Has Philip Bolton received payments from drug or device companies?

Yes. Drug and device makers reported $419 in general payments to Philip Bolton across 21 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Philip Bolton did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Philip Bolton come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Philip Bolton

Psychiatry · Milwaukie, ORNPI 1588692388

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 31.5% of the total. Reporting peaked in 2022 at $238 and has fallen 88.0% since, to $29 in 2023.

$419in general payments, 2019–2025

Across 21 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka America Pharmaceutical, Inc.$132
Lundbeck LLC$57
AbbVie$52
Sunovion Pharmaceuticals Inc.$49
Teva Pharmaceuticals USA, Inc.$41
Johnson & Johnson$39
plus $49 from 2 others

$1,804,975in research payments, 2019–2025

Across 168 payments — averaging $10,744 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Otsuka Pharmaceutical Development & Commercialization, Inc.$761K
Sage Therapeutics, LLC$554K
Arbor Pharmaceuticals, Inc.$191K
Acadia Pharmaceuticals Inc$180K
AbbVie$102K
Eisai Inc.$17K
plus $70 from 1 others

What the payments were for

Food & beverage$419100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka America Pharmaceutical, Inc.	6	$132
Lundbeck LLC	2	$57
AbbVie	3	$52
Sunovion Pharmaceuticals Inc.	3	$49
Teva Pharmaceuticals USA, Inc.	2	$41
Johnson & Johnson	2	$39
Bausch Health US, LLC	2	$25
Jazz Pharmaceuticals Inc.	1	$24

How this compares

$419 in reported general payments places this provider in the 85th percentile of 366 psychiatry providers in Oregon.

See all psychiatry providers in Oregon →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	19	$657
Fluoxetine Hcl	27	$284
Buspirone Hcl	13	$124

Paid to pharmacies, not to this prescriber.

Other psychiatry in Milwaukie

Alan YeoMilwaukie$1K
Warner SwarnerMilwaukie$369
Andrew WilliamsBeaverton$84K
Jacqueline AmatoMedford$27K
Alisha MorelandPortland$20K
Leigh Anne BresslerPortland$15K
John LipkinEugene$15K
Alfred LewyPortland$9K
Hernan SchmidtEugene$8K
Anca Maria BejenaruPortland$6K

See the full list for Oregon →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →